Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Harvard Business School
McKinsey
Mallinckrodt
McKesson

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

Litigation Details for Tris Pharma Inc. v. Actavis Laboratories FL Inc. (D. Del. 2014)

See Plans and Pricing

« Back to Dashboard

Tris Pharma Inc. v. Actavis Laboratories FL Inc. (D. Del. 2014)

Docket   Start Trial Date Filed 2014-10-15
Court District Court, D. Delaware Date Terminated
Cause 35:271 Patent Infringement Assigned To Gregory Moneta Sleet
Jury Demand None Referred To
Parties ACTAVIS INC.; ACTAVIS LABORATORIES FL INC.; ACTAVIS PHARMA INC.; ANDRX CORPORATION; PAR PHARMACEUTICAL COMPANIES INC.; PAR PHARMACEUTICAL INC.; TRIS PHARMA INC.
Patents 6,419,960; 7,691,880; 8,062,667; 8,287,903; 8,465,765; 8,563,033; 8,778,390; 8,956,649; 9,040,083
Attorneys Brenda L. Danek; Cynthia L Hardman; David A. Bilson; Derek James Fahnestock; Gregory K. Sobolski; Jack B. Blumenfeld; Jennifer Koh; Jennifer L. Ford; John C. Phillips , Jr.; Jordan P. Markham; Katharine Lester Mowery; Regina S.E. Murphy; Steven J. Fineman
Link to Docket External link to docket
Small Molecule Drugs cited in Tris Pharma Inc. v. Actavis Laboratories FL Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for Tris Pharma Inc. v. Actavis Laboratories FL Inc. (D. Del. 2014)

Date Filed Document No. Description Snippet Link To Document
2014-10-15 1 “Notification of Certification for U.S. Patent Nos. 8,062,667; 8,287,903; 8,465,765; 8,563,033 and 8,778,390…States Patent No. 8,465,765 (“the ’765 patent”), United States Patent No. 8,563,033 (“the ’033 patent”), …Actavis has infringed the ’765 patent, the ’033 patent, and the ’390 patent by submitting ANDA 206049 to… to infringement of the ’765 patent, the ’033 patent, and the ’390 patent; -15_ Case 1:14-ov-01309-UNA…after the expiration of the ’765 patent, the ’033 patent, the ’390 patent, or any later expiration of exclusivity External link to document
2017-09-05 161 1 and Cmax-2)." 153. U.S. Patent No. 6,419,960 ("Krishnamurthy") issued on July…#39;667 Patent, the '903 patent, the '765 patent, the '033 patent, the '390 patent, the ….S. Patent Nos. 8,46,765 ("the '765 patent"), 8,563,033 ("the '033 patent"…the '649 patent, and the '083 patent (collectively, "the patents-in-suit") are listed …The '667 patent is cited on the face of each of the patents-in-suit. The '667 patent expires on External link to document
2014-10-15 4 the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,465,765 B2; 8,563,033 B1; 8,778,390… 15 October 2014 1:14-cv-01309 830 Patent None District Court, D. Delaware External link to document
2015-12-18 92 Actavis”) alleging infringement of U.S. Patent Nos. 8,465,765, 8,563,033 and 8,778,390 in connection with…Actavis alleging infringement of U.S. Patent No. 8,956,649 (“the ’649 patent”) in Case 1:14-cv-01309-GMS Document…Actavis alleging infringement of U.S. Patent No. 9,040,083 (“the ’083 patent”) in connection with the filing… XR® product prior to the expiration of those patents; WHEREAS on May 15, 2015, Tris filed a …Quillivant XR® product prior to the expiration of that patent; WHEREAS on July 13, 2015, the parties External link to document
2015-12-21 93 quot;) alleging . infringement of U.S. Patent Nos. 8,465,765, 8,563,033 and 8,778,390 in connection with…alleging infringement of U.S. Patent No. 8,956,649 (''the '649 patent") in Case 1:14-cv-01309…alleging infringement of U.S. Patent No. 9,040,083 ("the '083 patent") in connection with … XR® product prior to the expiration of those patents; WHEREAS on May 15, 2015, Tris filed a…Quillivant XR® product prior to the expiration of that patent; WHEREAS on July 13, 2015, the parties External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Baxter
Medtronic
Johnson and Johnson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.